buprenorphine is first-line treatment for opioid use disorder, and one of the most promising

new ways to deliver it is via a long-acting injection. There are two variations of long-acting

injectable buprenorphine on the market, but what differentiates them, who might benefit, and how

well do they work? Find out in today's podcast.

Welcome to the Carlatte Psychiatry Podcast. This is your host, Dr. Noah Caperso, the editor-in-chief of the Carlat Addiction Treatment

Report, an associate clinical professor of psychiatry at the Yale University School of Medicine,

and Assistant Medical Director of Addiction Services at Connecticut Valley Hospital.

And I'm Geneva Valeska, a podcast coordinator here at The Carlet Report with the degree in

neuroscience and cognitive science. Long-acting buprenorphine has really changed the game for

opioid use disorder, opening the options available for patients and prescribers when it comes

to this life-saving medication.

Today we'll review and to consider long-acting injectable buprenorphine with a focus on two

currently available formulations, Sublocade and Brixadis. Both have a lot to offer, but there are

some key differences that clinicians need to consider when choosing the best option for their patients.

Right. Let's start with a little background.

Bupinorphine is a partial mu-opoe opioid receptor agonist and one of the most effective

medications for treating opioid use disorder. It's been around for decades in sublingual forms like

Suboxone, which is combined with naloxone in efforts to deter misuse, and formulation

without the naloxone component,

formerly known as subutex. And while sublingual buprenorphine can be effective for many of our

patients, adherence can be a challenge, with mortality rates spiking sixfold in the first month

after discontinuation. That's where long-acting formulations like sublocade and Brixati come in.

...